4-hydroxyphenylacetic acid propyl ester | 79419-45-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 4-hydroxyphenylacetic acid propyl ester
• 英文别名: n-propyl 4-hydroxyphenylacetate；3-propyl-4-hydroxyphenylacetate；propyl 2-(4-hydroxyphenyl)acetate
• CAS: 79419-45-7
• 化学式: C₁₁H₁₄O₃
• 分子量: 194.23
• InChiKey: MUQNRSMRGOMDNP-UHFFFAOYSA-N

物化性质

• 沸点：
  306.0±17.0 °C(Predicted)
• 密度：
  1.118±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-(3-bromopropoxy)-4-tert-butylmethyl-7-hydroxy-8-propylcoumarin 、 4-hydroxyphenylacetic acid propyl ester 在 potassium carbonate 作用下， 以 正己烷 、 二氯甲烷 、 丁酮 为溶剂， 生成 methyl 3-propyl-4-(3-(4-tert-butylmethyl-8-propyl-coumarinolyl-7-oxy)propylthio)phenyl-acetate
  参考文献：
  名称：

  Antidiabetic agents

  摘要：

  该发明涉及乙酰苯酚，可用作抗肥胖和抗糖尿病化合物。还公开了在治疗糖尿病和肥胖中使用这些化合物的组合物和方法，以及降低或调节甘油三酯水平和胆固醇水平，或提高高密度脂蛋白水平，或增加肠道蠕动或治疗动脉粥样硬化的方法。

  公开号：

  US05859051A1
• 作为产物：
  描述：

  丙醇 、 对羟基苯乙酸 在 盐酸 作用下， 生成 4-hydroxyphenylacetic acid propyl ester
  参考文献：
  名称：

  Ester derivatives of 2,6-bis(1-pyrrolidinylmethyl)-4-benzamidophenol as short-acting antiarrhythmic agents. 1

  摘要：

  In an effort to find a replacement for the iv antiarrhythmic drug lidocaine having reduced systemic and central nervous system effects, activity against supraventricular as well as ventricular arrhythmias, and a biological half-life of less than 15 min, derivatives of the orally active class Ic clinical agent 2,6-bis(1-pyrrolidinylmethyl)-4-benzamidophenol, 1 (ACC-9358), were synthesized and tested. Compounds with ester groups attached to the phenyl ring were either weakly active or toxic. Replacement of the formanilide function with alkyl esters afforded compounds with antiarrhythmic activity in the range of 1. When the ester carboxyl was separated from the bis(aminomethyl)phenol by methylene units, very short half-lives were observed in human blood. In general, these compounds also had low lipophilic character.

  DOI：

  10.1021/jm00128a037

文献信息

• Short-acting sedative hypnotic agents for anesthesia and sedation
  申请人：——

  公开号：US20030153554A1

  公开（公告）日：2003-08-14

  The invention provides compounds compositions and methods useful for inducing or maintaining general anesthesia or sedation in mammals.

  这项发明提供了一种用于在哺乳动物中诱导或维持全身麻醉或镇静的化合物组合物和方法。
• 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles
  申请人：Tsubouchi Hidetsugu

  公开号：US20060094767A1

  公开（公告）日：2006-05-04

  The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: wherein R 1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R 2 represents a group —OR 3 or the like, and R 3 represents a hydrogen atom, C1-C6 alkyl group or the like, or R 1 and —(CH 2 ) n R 2 may bind to each other together with carbon atoms adjacent thereto through nitrogen atoms so as to form a spiro ring represented by the general formula (H): wherein R 41 is hydrogen, C1-C6 alkyl group or the like. The present compound has an excellent bactericidal action against Mycobacterium tuberculosis , multi-drug-resistant Mycobacterium tuberculosis , and atypical acid-fast bacteria.

  本发明提供了一种2,3-二氢-6-硝基咪唑并[2,1-b]噁唑化合物，其通式如下：其中，R1代表氢原子或C1-C6烷基，n代表0到6的整数，R2代表—OR3或类似的基团，R3代表氢原子、C1-C6烷基或类似的基团，或者R1和—(CH2)nR2可以通过相邻的碳原子通过氮原子结合在一起形成一个螺环，其通式为（H）：其中，R41为氢、C1-C6烷基或类似的基团。该化合物对结核分枝杆菌、多药耐药结核分枝杆菌和非典型酸性快速细菌具有优异的杀菌作用。
• Soft .beta.-adrenergic blocking agents
  申请人：——

  公开号：US05202347A1

  公开（公告）日：1993-04-13

  New soft .beta.-adrenergic blocking agents, useful in the treatment or prevention of cardiovascular disorders and in the treatment of glaucoma, have the formula ##STR1## wherein n is an integer from 0 to 10; R is C.sub.6 -C.sub.12 cycloalkyl-C.sub.p H.sub.2p --, C.sub.6 -C.sub.18 polycycloalkyl-C.sub.p H.sub.2p --, C.sub.6 -C.sub.18 polycycloalkenyl-C.sub.p H.sub.2p -- or C.sub.6 -C.sub.12 cycloalkenyl-C.sub.p H.sub.2p -- (wherein p is 0, 1, 2 or 3), or together with the adjacent ##STR2## group represents a variety of other complex ester groupings; R.sub.1 is C.sub.1 -C.sub.7 alkyl; and Ar is a divalent radical containing at least one aromatic nucleus. The corresponding pharmaceutically acceptable acid addition salts are also described.

  新软性.beta.-肾上腺素受体阻滞剂，适用于心血管疾病的治疗或预防以及青光眼的治疗，其化学式为##STR1## 其中n为0至10的整数；R为C.sub.6-C.sub.12环烷基-C.sub.p H.sub.2p --，C.sub.6-C.sub.18多环烷基-C.sub.p H.sub.2p --，C.sub.6-C.sub.18多环烯基-C.sub.p H.sub.2p --或C.sub.6-C.sub.12环烯基-C.sub.p H.sub.2p --（其中p为0、1、2或3），或与相邻的##STR2##基团一起代表各种其他复杂的酯基团；R.sub.1为C.sub.1-C.sub.7烷基；Ar为至少含有一个芳香族核的二价基团。还描述了相应的药物可接受的酸盐。
• Soft .beta.-drenegic blocking agents
  申请人：——

  公开号：US05576332A1

  公开（公告）日：1996-11-19

  New soft .beta.-adrenergic blocking agents, useful in the treatment or prevention of cardiovascular disorders and in the treatment of glaucoma, have the formula ##STR1## wherein n is an integer from 0 to 10; R is C.sub.6 -C.sub.12 cycloalkyl-C.sub.p H.sub.2p --, C.sub.6 -C.sub.18 polycycloalkyl-C.sub.p H.sub.2p --, C.sub.6 -C.sub.18 polycycloalkenyl-C.sub.p H.sub.2p -- or C.sub.6 -C.sub.12 cycloalkenyl-C.sub.p H.sub.2p -- (wherein p is 0, 1, 2 or 3), or together with the adjacent ##STR2## group represents a variety of other complex ester groupings; R.sub.1 is C.sub.1 -C.sub.7 alkyl; and Ar is a divalent radical containing at least one aromatic nucleus. The corresponding pharmaceutically acceptable acid addition salts are also described.

  新软性β-肾上腺素阻滞剂，可用于治疗或预防心血管疾病和治疗青光眼，其化学式为##STR1##其中n为0至10的整数；R为C.sub.6-C.sub.12环烷基-C.sub.p H.sub.2p --、C.sub.6-C.sub.18多环烷基-C.sub.p H.sub.2p --、C.sub.6-C.sub.18多环烯基-C.sub.p H.sub.2p --或C.sub.6-C.sub.12环烯基-C.sub.p H.sub.2p --（其中p为0、1、2或3），或与相邻的##STR2##基团一起表示其他复杂的酯基团；R.sub.1为C.sub.1-C.sub.7烷基；Ar为至少含有一个芳香核的二价基团。还描述了相应的药用酸盐。
• SHORT-ACTING SEDATIVE HYPNOTIC AGENTS FOR ANESTHESIA AND SEDATION
  申请人：Jenkins Thomas E.

  公开号：US20090253787A1

  公开（公告）日：2009-10-08

  The invention provides compounds compositions and methods useful for inducing or maintaining general anesthesia or sedation in mammals.

  本发明提供了一种化合物、组合物和方法，用于在哺乳动物中诱导或维持全身麻醉或镇静状态。